Macron
Controversy over the efficacy of a novel coronavirus infection vaccine jointly developed by AstraZeneca and Oxford University, a multinational pharmaceutical company in the UK and Sweden, is spreading in Europe. Even French President Emmanuel Macron joined with the topic of’dance theory over 65′. The Korean government has decided to introduce 2.19 million people with this vaccine in the first half of this year. Accordingly, attention is drawn to the results of the first external expert advisory meeting scheduled to be announced on the 1st of this vaccine, which is currently under license review in Korea.
Government plans to inoculate 560,000 elderly people in nursing homes
Ministry of Food and Drug Safety to announce the appropriateness of vaccination today
Italy recommends other vaccines over the age of 55
Astra’s “Generation of Antibodies for the Elderly”
President Macron said in a media conference on the 29th of last month, “Officially speaking, AstraZeneca vaccine is not recommended to those aged 60 to 65, and it is considered useless to people over 65,” AFP reported. . “There is only very little information (for this age group),” Macron explained.
Macron pointed out the’lack of information’ because the clinical trial subjects were limited to young people. On December 8, last year, AstraZeneca published the results of a phase 3 clinical trial confirming the efficacy of the vaccine in the medical journal Lancet. According to this, 9.7% of the participants in clinical trials in the UK, Brazil, and South Africa were over 65 years old. Compared to the Pfizer vaccine, which is 22% of the subjects aged 65 or older in the phase 3 clinical trial, the proportion of the elderly is small.
Accordingly, there is a growing concern about the vaccination of the elderly with the AstraZeneca vaccine. On the 27th of last month, the immunization committee of the Robert Koch Institute (RKI) in Germany said, “Because the number of participants in clinical trials in the age group over 65 is small, we cannot conclude on the efficacy and safety for the elderly.” The Italian Medicines Agency (AIFA) also approved the AstraZeneca vaccine on the 30th, recommending that people over the age of 55 get another vaccine. However, the European Medicines Agency (EMA) said on the 29th that, “As a result of evaluating the quality, safety, and efficacy of the AstraZeneca vaccine, conditional approval of the use of the vaccine is recommended for 18 years of age or older.
Accordingly, the Korean government’s concerns are deepening. This is because SK Bioscience in Korea decided to release the volume, including the first introduction, which was commissioned and produced in Korea in the first half. It plans to inoculate 566,000 elderly people living in group facilities such as nursing homes and nursing homes and workers in high-risk medical institutions. The Ministry of Food and Drug Safety held a’Corona 19 Vaccine Safety and Effectiveness Verification Advisory Group’ (Advisory Group) meeting consisting of external experts on the 31st to discuss the safety and efficacy of this vaccine, clinical significance, and the appropriateness of the target patient. It is released on the 1st.
AstraZeneca is opposed to the’older uselessness’ of vaccines. The company made a statement and emphasized that “the elderly people have reached 100% of the antibody production rate after the second vaccination.” “I have doubts about Macron’s demand management,” said John Bell, a professor at Oxford University, who co-developed the vaccine. “Without a (home-made) vaccine, the best thing to do is to reduce demand.” .
Reporter Kim Hong-bum [email protected]